Primary Angioplasty For Patients in Cardiogenic Shock: Optimal Management

Overview

Journal Interv Cardiol

Date 2018 Mar 29

PMID 29588703

Citations 1

Authors

Jubin Joseph

Tiffany Patterson

Satpal Arri

Hannah McConkey

Simon R Redwood

Affiliations

Soon will be listed here.

Abstract

Cardiogenic shock complicates approximately 5-10 % of all MI events and remains the most common cause of death among MI cases. Over the past few decades, the mortality rate associated with cardiogenic shock has decreased with the introduction of early revascularisation, although there are limited data for patients with triple-vessel disease and left main stem disease. In more recent years, there have been a number of advances in the mechanical circulatory support devices that can help improve the haemodynamics of patients in cardiogenic shock. Despite these advances, together with progress in the use of inotropes and vasopressors, cardiogenic shock remains associated with high morbidity and mortality rates. This review will outline the management of cardiogenic shock complicating acute MI with a smajor focus on revascularisation techniques and the use of mechanical circulatory support devices.

Citing Articles

Steps To Prevent Mortality in a Patient with Coinciding Severe Sepsis and Cardiogenic Shock Post-Non-ST-Elevation Myocardial Infarction (NSTEMI): A Case Report.

Nagaratnam J, Farooq R, El Dirani M, Mathew S, Ogwu C, Kholoki S Cureus. 2023; 14(11):e32086.

PMID: 36600844 PMC: 9803867. DOI: 10.7759/cureus.32086.

References

OGara P, Kushner F, Ascheim D, Casey Jr D, Chung M, de Lemos J . 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration.... Catheter Cardiovasc Interv. 2013; 82(1):E1-27. DOI: 10.1002/ccd.24776. View

Hochman J, Boland J, Sleeper L, Porway M, Brinker J, Col J . Current spectrum of cardiogenic shock and effect of early revascularization on mortality. Results of an International Registry. SHOCK Registry Investigators. Circulation. 1995; 91(3):873-81. DOI: 10.1161/01.cir.91.3.873. View

Seyfarth M, Sibbing D, Bauer I, Frohlich G, Bott-Flugel L, Byrne R . A randomized clinical trial to evaluate the safety and efficacy of a percutaneous left ventricular assist device versus intra-aortic balloon pumping for treatment of cardiogenic shock caused by myocardial infarction. J Am Coll Cardiol. 2008; 52(19):1584-8. DOI: 10.1016/j.jacc.2008.05.065. View

Aissaoui N, Puymirat E, Tabone X, Charbonnier B, Schiele F, Lefevre T . Improved outcome of cardiogenic shock at the acute stage of myocardial infarction: a report from the USIK 1995, USIC 2000, and FAST-MI French nationwide registries. Eur Heart J. 2012; 33(20):2535-43. DOI: 10.1093/eurheartj/ehs264. View

Tousek P, Rokyta R, Tesarova J, Pudil R, Belohlavek J, Stasek J . Routine upfront abciximab versus standard periprocedural therapy in patients undergoing primary percutaneous coronary intervention for cardiogenic shock: The PRAGUE-7 Study. An open randomized multicentre study. Acute Card Care. 2011; 13(3):116-22. DOI: 10.3109/17482941.2011.567282. View

Unverzagt S, Wachsmuth L, Hirsch K, Thiele H, Buerke M, Haerting J . Inotropic agents and vasodilator strategies for acute myocardial infarction complicated by cardiogenic shock or low cardiac output syndrome. Cochrane Database Syst Rev. 2014; (1):CD009669. DOI: 10.1002/14651858.CD009669.pub2. View

Souckova L, Opatrilova R, Suk P, Cundrle Jr I, Pavlik M, Zvonicek V . Impaired bioavailability and antiplatelet effect of high-dose clopidogrel in patients after cardiopulmonary resuscitation (CPR). Eur J Clin Pharmacol. 2012; 69(3):309-17. DOI: 10.1007/s00228-012-1360-0. View

Thiele H, Sick P, Boudriot E, Diederich K, Hambrecht R, Niebauer J . Randomized comparison of intra-aortic balloon support with a percutaneous left ventricular assist device in patients with revascularized acute myocardial infarction complicated by cardiogenic shock. Eur Heart J. 2005; 26(13):1276-83. DOI: 10.1093/eurheartj/ehi161. View

Hochman J, Sleeper L, WEBB J, Sanborn T, White H, Talley J . Early revascularization in acute myocardial infarction complicated by cardiogenic shock. SHOCK Investigators. Should We Emergently Revascularize Occluded Coronaries for Cardiogenic Shock. N Engl J Med. 1999; 341(9):625-34. DOI: 10.1056/NEJM199908263410901. View

10.

Singh M, White J, Hasdai D, Hodgson P, Berger P, Topol E . Long-term outcome and its predictors among patients with ST-segment elevation myocardial infarction complicated by shock: insights from the GUSTO-I trial. J Am Coll Cardiol. 2007; 50(18):1752-8. DOI: 10.1016/j.jacc.2007.04.101. View

11.

Mehta R, Lopes R, Ballotta A, Frigiola A, Sketch Jr M, Bossone E . Percutaneous coronary intervention or coronary artery bypass surgery for cardiogenic shock and multivessel coronary artery disease?. Am Heart J. 2010; 159(1):141-7. DOI: 10.1016/j.ahj.2009.10.035. View

12.

Goldberg R, Spencer F, Gore J, Lessard D, Yarzebski J . Thirty-year trends (1975 to 2005) in the magnitude of, management of, and hospital death rates associated with cardiogenic shock in patients with acute myocardial infarction: a population-based perspective. Circulation. 2009; 119(9):1211-9. PMC: 2730832. DOI: 10.1161/CIRCULATIONAHA.108.814947. View

13.

WEBB J, Carere R, Hilton J, Rabinowitz A, Buller E, Dodek A . Usefulness of coronary stenting for cardiogenic shock. Am J Cardiol. 1997; 79(1):81-4. DOI: 10.1016/s0002-9149(96)00683-2. View

14.

Sheu J, Tsai T, Lee F, Fang H, Sun C, Leu S . Early extracorporeal membrane oxygenator-assisted primary percutaneous coronary intervention improved 30-day clinical outcomes in patients with ST-segment elevation myocardial infarction complicated with profound cardiogenic shock. Crit Care Med. 2010; 38(9):1810-7. DOI: 10.1097/CCM.0b013e3181e8acf7. View

15.

White H, Assmann S, Sanborn T, Jacobs A, Webb J, Sleeper L . Comparison of percutaneous coronary intervention and coronary artery bypass grafting after acute myocardial infarction complicated by cardiogenic shock: results from the Should We Emergently Revascularize Occluded Coronaries for Cardiogenic Shock.... Circulation. 2005; 112(13):1992-2001. DOI: 10.1161/CIRCULATIONAHA.105.540948. View

16.

Prondzinsky R, Lemm H, Swyter M, Wegener N, Unverzagt S, Carter J . Intra-aortic balloon counterpulsation in patients with acute myocardial infarction complicated by cardiogenic shock: the prospective, randomized IABP SHOCK Trial for attenuation of multiorgan dysfunction syndrome. Crit Care Med. 2009; 38(1):152-60. DOI: 10.1097/CCM.0b013e3181b78671. View

17.

Thiele H, Zeymer U, Neumann F, Ferenc M, Olbrich H, Hausleiter J . Intra-aortic balloon counterpulsation in acute myocardial infarction complicated by cardiogenic shock (IABP-SHOCK II): final 12 month results of a randomised, open-label trial. Lancet. 2013; 382(9905):1638-45. DOI: 10.1016/S0140-6736(13)61783-3. View

18.

Webb J, Lowe A, Sanborn T, White H, Sleeper L, Carere R . Percutaneous coronary intervention for cardiogenic shock in the SHOCK trial. J Am Coll Cardiol. 2003; 42(8):1380-6. DOI: 10.1016/s0735-1097(03)01050-7. View

19.

Chan A, Chew D, Bhatt D, Moliterno D, Topol E, Ellis S . Long-term mortality benefit with the combination of stents and abciximab for cardiogenic shock complicating acute myocardial infarction. Am J Cardiol. 2002; 89(2):132-6. DOI: 10.1016/s0002-9149(01)02188-9. View

20.

Holmes Jr D, Bates E, Kleiman N, Sadowski Z, Horgan J, Morris D . Contemporary reperfusion therapy for cardiogenic shock: the GUSTO-I trial experience. The GUSTO-I Investigators. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries. J Am Coll Cardiol. 1995; 26(3):668-74. DOI: 10.1016/0735-1097(95)00215-p. View